Cited by 186Melanoma and MAPK PathwaysProtein Kinase Regulation and GTPase SignalingProtein Tyrosine Phosphatases

The DOI matches its Crossref record; 68 of the 74 references it cites were found in a registry or an index.

Targeting the Mitogen-Activated Protein Kinase Pathway: Physiological Feedback and Drug Response

Open access

Pratilas, Christine A., Solit, David B.·2010·Clinical Cancer Research

DOI 10.1158/1078-0432.ccr-09-3064PMC PMC2912210

Open this paper in CoChat — free account

Abstract

Mitogen-activated protein kinase (MAPK) pathway activation is a frequent event in human cancer and is often the result of activating mutations in the BRAF and RAS oncogenes. Targeted inhibitors of BRAF and its downstream effectors are in various stages of preclinical and clinical development. These agents offer the possibility of greater efficacy and less toxicity than current therapies for tumors driven by oncogenic mutations in the MAPK pathway. Early clinical results with the BRAF-selective inhibitor PLX4032 suggest that this strategy will prove successful in a select group of patients whose tumors are driven by V600E BRAF. Relief of physiologic feedback upon pathway inhibition may, however, attenuate drug response and contribute to the development of acquired resistance. An improved understanding of the adaptive response of cancer cells to MAPK pathway inhibition may thus aid in the identification of those patients most likely to respond to targeted pathway inhibitors and provide a rational basis for tailored combination strategies. Clin Cancer Res; 16(13); 3329–34. ©2010 AACR.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-09-3064

Cites

68 of 68 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
TGF-β SIGNAL TRANSDUCTION
Massagué, J. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.753 · Cited by 7,571
BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D. P., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P. W., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,060
PD 098059 Is a Specific Inhibitor of the Activation of Mitogen-activated Protein Kinase Kinase in Vitro and in Vivo
Alessi, D. R., Cuenda, A., Cohen, P., Dudley, D. T., & Saltiel, A. R. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.46.27489 · Cited by 3,374
Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Wan, P., Garnett, M. J., Roe, S. M., Lee, S., Niculescu‐Duvaz, D., Good, V. M., Cancer Genome Project, Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,863
RAS oncogenes: the first 30 years
Malumbres, M., & Barbacid, M. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1097 · Cited by 1,902
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikakos, P. I., Zhang, C., Bollag, G. E., Shokat, K. M., & Rosen, N. X. (2010) · Nature · doi:10.1038/nature08902 · Cited by 1,841
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Hatzivassiliou, G., Song, K. W., Yen, I., Brandhuber, B. J., Anderson, D. J., Alvarado, R., Ludlam, M. J. C., Stokoe, D., Gloor, S. L., Vigers, G. P. A., et al. (2010) · Nature · doi:10.1038/nature08833 · Cited by 1,649
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
Heidorn, S. J., Milagre, C. S., Whittaker, S. R., Nourry, A., Niculescu‐Duvaz, I., Dhomen, N. S., Hussain, J., Reis-Filho, J. S., Springer, C. J., Pritchard, C. A., et al. (2010) · Cell · doi:10.1016/j.cell.2009.12.040 · Cited by 1,497
Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer
Carracedo, A., Ma, L., Teruya-Feldstein, J., Rojo, F., Salmena, L., Alimonti, A., Egia, A., Sasaki, A. T., Thomas, G., Kozma, S. C., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34739 · Cited by 1,381

Show all 74 references

Research works printed but not linked: 1

Tsai, 2006, Development of a novel inhibitor of cogenic b-raf, Proc Amer Assoc Cancer Res, 47, 2412

Sorted by citations

Targeting the MAPK–RAS–RAF signaling pathway in cancer therapy
Santarpia, L., Lippman, S. M., & El‐Naggar, A. K. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.645805 · Cited by 1,082
Signal Transduction in CancerPreprint
Sever, R., & Brugge, J. S. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006098 · Cited by 1,028
Vemurafenib: the first drug approved for BRAF-mutant cancer
Bollag, G. E., Tsai, J. Y., Zhang, J., Zhang, C., Ibrahim, P. N., Nolop, K. B., & Hirth, P. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3847 · Cited by 854
The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches
Luca, A. D., Maiello, M. R., D’Alessio, A., Pergameno, M., & Normanno, N. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.639361 · Cited by 748
Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging
Steelman, L. S., Chappell, W. H., Abrams, S. L., Kempf, C. R., Long, J., Laidler, P., Mijatovic, S., Maksimovic-Ivanic, D., Stivala, F., Mazzarino, M. C., et al. (2011) · Aging · doi:10.18632/aging.100296 · Cited by 553
Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.
Morris, E. J., Jha, S., Restaino, C. R., Dayananth, P., Zhu, H., Cooper, A., Carr, D., Deng, Y., Jin, W., Black, S., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0070 · Cited by 676
Dual‐specificity MAP kinase phosphatases (MKPs): Shaping the outcome of MAP kinase signalling
Caunt, C. J., & Keyse, S. M. (2013) · The FEBS Journal · doi:10.1111/j.1742-4658.2012.08716.x · Cited by 535
RAF protein-serine/threonine kinases: Structure and regulation
Roskoski, R. J. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.07.092 · Cited by 372
KRAS mutation in pancreatic cancer
Luo, J. (2021) · Seminars in Oncology · doi:10.1053/j.seminoncol.2021.02.003 · Cited by 360
Therapeutic Strategies for Targeting Ras Proteins
Gysin, S., Salt, M. B., Young, A. E., & McCormick, F. (2011) · Genes & Cancer · doi:10.1177/1947601911412376 · Cited by 329
An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance.Preprint
Zuber, J., Rappaport, A. R., Luo, W., Wang, E., Chen, C., Vaseva, A. V., Shi, J.-W., Weissmueller, S., Fellmann, C., Taylor, M. J., et al. (2011) · Genes & Development · doi:10.1101/gad.17269211 · Cited by 289
Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy
Steelman, L. S., Franklin, R. A., Abrams, S. L., Chappell, W. H., Kempf, C., Bäsecke, J., Stivala, F., Donia, M., Fagone, P., Nicoletti, F., et al. (2011) · Leukemia · doi:10.1038/leu.2011.66 · Cited by 271
Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032
Rubinstein, J. C., Sznol, M., Pavlick, A. C., Ariyan, S., Cheng, E., Bacchiocchi, A., Kluger, H. M., Narayan, D., & Halaban, R. (2010) · Journal of Translational Medicine · doi:10.1186/1479-5876-8-67 · Cited by 255
Atypical Melanocytic Proliferations and New Primary Melanomas in Patients With Advanced Melanoma Undergoing Selective BRAF Inhibition
Zimmer, L., Hillen, U., Livingstone, E., Lacouture, M. E., BUSAM, K. J., Carvajal, R. D., Egberts, F., Hauschild, A., Kashani–Sabet, M., Goldinger, S. M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.1660 · Cited by 234
Oncogenic and Wild-type Ras Play Divergent Roles in the Regulation of Mitogen-Activated Protein Kinase Signaling
Young, A., Lou, D., & McCormick, F. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0231 · Cited by 211
FOXM1 (Forkhead box M1) in Tumorigenesis
Wierstra, I. (2013) · Advances in cancer research · doi:10.1016/b978-0-12-407190-2.00016-2 · Cited by 190
Myc and Ras oncogenes engage different energy metabolism programs and evoke distinct patterns of oxidative and DNA replication stress
Maya‐Mendoza, A., Ostráková, J., Košař, M., Hall, A., Dušková, P., Mistrík, M., Merchut‐Maya, J. M., Hodný, Z., Bártková, J., Christensen, C., et al. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.11.001 · Cited by 179
The Next Generation of Glioma Biomarkers: MGMT Methylation, BRAF Fusions and IDH1 Mutations
von Deimling, A., Korshunov, A., & Hartmann, C. J. (2010) · Brain Pathology · doi:10.1111/j.1750-3639.2010.00454.x · Cited by 178
Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways
McCubrey, J. A., Steelman, L. S., Kempf, C., Chappell, W. H., Abrams, S. L., Stivala, F., Malaponte, G., Nicoletti, F., Libra, M., Bäsecke, J., et al. (2011) · Journal of Cellular Physiology · doi:10.1002/jcp.22647 · Cited by 177
Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS -Mutant Lung Cancer
Kitai, H., Ebi, H., Tomida, S., Floros, K. V., Kotani, H., Adachi, Y., Oizumi, S., Nishimura, M., Faber, A. C., & Yano, S. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1377 · Cited by 162
Clinicopathological relevance of BRAF mutations in human cancer
Pakneshan, S., Salajegheh, A., Anthony Smith, R., & King-Yin Lam, A. (2013) · Pathology · doi:10.1097/pat.0b013e328360b61d · Cited by 156
Regulation and function of TPL-2, an IκB kinase-regulated MAP kinase kinase kinase
Gantke, T., Sriskantharajah, S., & Ley, S. C. (2010) · Cell Research · doi:10.1038/cr.2010.173 · Cited by 154
MEK-Independent Survival of B-RAFV600E Melanoma Cells Selected for Resistance to Apoptosis Induced by the RAF Inhibitor PLX4720
Jiang, C. C., Lai, F., Thorne, R. F., Yang, F., Liu, H., Hersey, P., & Zhang, X. D. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2225 · Cited by 122
Splicing factor hnRNP A2 activates the Ras-MAPK-ERK pathway by controlling A-Raf splicing in hepatocellular carcinoma development
Shilo, A., Ben-Hur, V., Denichenko, P., Stein, I., Pikarsky, E., Rauch, J., Kölch, W., Zender, L., & Karni, R. (2014) · RNA · doi:10.1261/rna.042259.113 · Cited by 113
Inhibition of vemurafenib-resistant melanoma by interference with pre-mRNA splicing
Salton, M., Kasprzak, W. K., Voss, T. C., Shapiro, B. A., Poulikakos, P. I., & Misteli, T. (2015) · Nature Communications · doi:10.1038/ncomms8103 · Cited by 113
Quantifying factors for the success of stratified medicine
Trusheim, M. R., Burgess, B., Hu, S. X., Long, T., Averbuch, S. D., Flynn, A. A., Lieftucht, A., Mazumder, A., Milloy, J., Shaw, P. M., et al. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3557 · Cited by 104
Mitogen-activated protein kinase signaling pathway in oral cancer (Review)
Peng, Q., Deng, Z., Pan, H., Gu, L., Liu, O., & Tang, Z. (2017) · Oncology Letters · doi:10.3892/ol.2017.7491 · Cited by 103
B-Raf and the inhibitors: from bench to bedside
Huang, T., Karsy, M. J., Zhuge, J., Zhong, M., & Liu, D. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-30 · Cited by 103
Focal Adhesion Kinase Regulates the DNA Damage Response and Its Inhibition Radiosensitizes Mutant KRAS Lung Cancer
Tang, K.-J., Constanzo, J. D., Venkateswaran, N., Melegari, M., Ilcheva, M., Morales, J. C., Skoulidis, F., Heymach, J. V., Boothman, D. A., & Scaglioni, P. P. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2603 · Cited by 91
SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors
Lu, H., Liu, C., Velazquez, R., Wang, H., Dunkl, L. M., Kazic-Legueux, M., Haberkorn, A., Billy, E., Manchado, E., Brachmann, S. M., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0852 · Cited by 90
The ERK cascade inhibitors: Towards overcoming resistance
Maik-Rachline, G., & Seger, R. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2015.12.001 · Cited by 91
Thyroid Cancer—Indications and Opportunities for Positron Emission Tomography/Computed Tomography Imaging
Abraham, T., & Schöder, H. M. (2011) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2010.10.006 · Cited by 78
Receptor tyrosine kinases and their activation in melanoma
Easty, D. J., Gray, S. G., O'Byrne, K. J., O’Donnell, D., & Bennett, D. C. (2011) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2011.00836.x · Cited by 79
Putting the pieces together: How is the mitochondrial pathway of apoptosis regulated in cancer and chemotherapy?
Elkholi, R., Renault, T. T., Serasinghe, M. N., & Chipuk, J. E. (2014) · Cancer & Metabolism · doi:10.1186/2049-3002-2-16 · Cited by 77
The molecular biology of colorectal carcinoma and its implications: A review
Harrison, S., & Benziger, H. (2011) · The Surgeon · doi:10.1016/j.surge.2011.01.011 · Cited by 71
Recent Progress in the Design, Study, and Development of c-Jun N-Terminal Kinase Inhibitors as Anticancer Agents
Messoussi, A., Feneyrolles, C., Bros, A., Deroide, A., Daydé-Cazals, B., Chevé, G., Hijfte, N. V., Fauvel, B., Bougrin, K., & Yasri, A. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.09.007 · Cited by 72
Anthracyclines and Mitochondria
Mordente, A., Meucci, E., Silvestrini, A., Martorana, G. E., & Giardina, B. (2011) · Advances in experimental medicine and biology · doi:10.1007/978-94-007-2869-1_18 · Cited by 68
Application of Multiplexed Kinase Inhibitor Beads to Study Kinome Adaptations in Drug-Resistant Leukemia
Cooper, M. J., Cox, N. J., Zimmerman, E. I., Dewar, B. J., Duncan, J. S., Whittle, M. C., Nguyen, T., Jones, L., Roy, S. G., Smalley, D. M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066755 · Cited by 67
A Review of the Molecular Pathways Involved in Resistance to BRAF Inhibitors in Patients with Advanced-Stage Melanoma
Tian, Y., & Guo, W. (2020) · Medical Science Monitor · doi:10.12659/msm.920957 · Cited by 71
c-Myc Regulates RNA Splicing of the A-Raf Kinase and Its Activation of the ERK Pathway
Rauch, J., Moran‐Jones, K., Albrecht, V. S., Schwarzl, T., Hunter, K. D., Gires, O., & Kölch, W. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4447 · Cited by 67
RAS signaling pathway mutations and hypertrophic cardiomyopathy: getting into and out of the thick of it
Gelb, B. D., & Tartaglia, M. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46399 · Cited by 65
RASA1-dependent cellular export of collagen IV controls blood and lymphatic vascular development
Chen, D., Teng, J. M. C., North, P. E., Lapinski, P. E., & King, P. D. (2019) · Journal of Clinical Investigation · doi:10.1172/jci124917 · Cited by 62
MEK inhibitors as a chemotherapeutic intervention in multiple myeloma
Leow, C. C.-Y., Gerondakis, S., & Spencer, A. (2013) · Blood Cancer Journal · doi:10.1038/bcj.2013.1 · Cited by 61
Quercetin preferentially induces apoptosis in KRAS‐mutant colorectal cancer cells via JNK signaling pathways
Yang, Y., Wang, T., Chen, D., Ma, Q., Zheng, Y., Liao, S., Wang, Y., & Zhang, J. (2018) · Cell Biology International · doi:10.1002/cbin.11055 · Cited by 61
Targeting de novo lipid synthesis induces lipotoxicity and impairs DNA damage repair in glioblastoma mouse models
Eyme, K. M., Sammarco, A., Jha, R., Mnatsakanyan, H., Pechdimaljian, C., de Carvalho, L. A., Neustadt, R., Moses, C., Alnasser, A. A., Tardiff, D. F., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abq6288 · Cited by 58
Gaining momentum: New options and opportunities for the treatment of advanced melanoma
Michielin, O. A., & Höeller, C. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.05.012 · Cited by 60
GABA B Receptor Complex as a Potential Target for Tumor Therapy
Jiang, X., Su, L., Zhang, Q., He, C., Zhang, Z., Yi, P., & Liu, J. (2012) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155412438105 · Cited by 55
Continual and partial MEK inhibition ameliorates cardio-facio-cutaneous phenotypes in zebrafish
Anastasaki, C., Rauen, K. A., & Patton, E. E. (2012) · Disease Models & Mechanisms · doi:10.1242/dmm.008672 · Cited by 55
Prognostic value of RKIP and p-ERK in gastric cancer
Fujimori, Y., Inokuchi, M., Takagi, Y., Kato, K., Kojima, K., & Sugihara, K. (2012) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-31-30 · Cited by 55
Monitoring Chemotherapeutic Response by Hyperpolarized 13C-Fumarate MRS and Diffusion MRI
Mignion, L., Dutta, P., Martinez, G. V., Foroutan, P., Gillies, R. J., & Jordan, B. F. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1914 · Cited by 53
Trametinib (GSK1120212) in the treatment of melanoma
Salama, A. K. S., & Kim, K. B. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.770475 · Cited by 56
Estrogenic activity and cytotoxicity of six anticancer drugs detected in water systems
Parrella, A., Lavorgna, M., Criscuolo, E., Russo, C., & Isidori, M. (2014) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2014.03.050 · Cited by 51
Systems-wide Analysis of K-Ras, Cdc42, and PAK4 Signaling by Quantitative Phosphoproteomics
Gnad, F., Young, A. E., Zhou, W., Lyle, K. S., Ong, C. C., Stokes, M. P., Silva, J. C., Belvin, M. P., Friedman, L. S., Koeppen, H., et al. (2013) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m112.027052 · Cited by 52
To Eat and to Be Eaten: Mutual Metabolic Adaptations of Immune Cells and Intracellular Bacterial Pathogens upon Infection
Eisenreich, W., Rudel, T., Heesemann, J., & Goebel, W. (2017) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2017.00316 · Cited by 53
Isoform-selective activity-based profiling of ERK signaling
Shin, M., Franks, C. E., & Hsu, K. (2018) · Chemical Science · doi:10.1039/c8sc00043c · Cited by 50
Ricin and Shiga Toxins: Effects on Host Cell Signal Transduction
Jandhyala, D. M., Thorpe, C. M., & Magun, B. E. (2011) · Current topics in microbiology and immunology · doi:10.1007/82_2011_181 · Cited by 48
Sorafenib Inhibition of Mcl-1 Accelerates ATRA-Induced Apoptosis in Differentiation-Responsive AML Cells
Wang, R., Xia, L., Gabrilove, J. L., Waxman, S., & Jing, Y. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0663 · Cited by 49
Resistance to Chemotherapy and Molecularly Targeted Therapies: Rationale for Combination Therapy in Malignant Melanoma
Wu, S., & Singh, R. K. (2011) · Current Molecular Medicine · doi:10.2174/156652411800615153 · Cited by 47
The two faces of FBW7 in cancer drug resistance
Wang, Z. P., Fukushima, H., Gao, D., Inuzuka, H., Wan, L., Lau, A. W., Liu, P., & Wei, W. (2011) · BioEssays · doi:10.1002/bies.201100101 · Cited by 45
Cantharidin suppressed breast cancer MDA-MB-231 cell growth and migration by inhibiting MAPK signaling pathway
Gu, X., Xu, L., Zhao, H., Gu, J., & Xie, X. (2017) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x20175920 · Cited by 44
Synthesis of novel 1,2-bis-quinolinyl-1,4-naphthoquinones: ERK2 inhibition, cytotoxicity and molecular docking studies
Aly, A. A., El‐Sheref, E. M., Bakheet, M. E. M., Mourad, M. A. E., Brown, A. B., Bräse, S., Nieger, M., & Ibrahim, M. A. A. (2018) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2018.09.017 · Cited by 43
Discovery of 1-(1H-Pyrazolo[4,3-c]pyridin-6-yl)urea Inhibitors of Extracellular Signal-Regulated Kinase (ERK) for the Treatment of Cancers
Lim, J., Kelley, E. H., Methot, J. L., Zhou, H., Petrocchi, A., Chen, H., Hill, S. E., Hinton, M. C., Hruza, A. W., Jung, J. O., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00708 · Cited by 40
RN181 suppresses hepatocellular carcinoma growth by inhibition of the ERK/MAPK pathway
Wang, S., Huang, X., Li, Y., Lao, H., Zhang, Y., Dong, H., Xu, W., Li, J., & Li, M. (2011) · Hepatology · doi:10.1002/hep.24291 · Cited by 40
Biological characteristics of pancreatic ductal adenocarcinoma: Initiation to malignancy, intracellular to extracellular
Li, O., Li, L., Sheng, Y., Ke, K., Wu, J., Mou, Y., Liu, M., & Jin, W. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216391 · Cited by 38
ERK/pERK expression and B-raf mutations in colon adenocarcinomas: correlation with clinicopathological characteristics
Levidou, G., Saetta, A. A., Gigelou, F., Κάρλου, Μ., Papanastasiou, P., Stamatelli, A., Kavantzas, N., Michalopoulos, N. V., Agrogiannis, G. D., Patsouris, E., et al. (2012) · World Journal of Surgical Oncology · doi:10.1186/1477-7819-10-47 · Cited by 38
Quantitative implementation of the endogenous molecular–cellular network hypothesis in hepatocellular carcinoma
Wang, G., Zhu, X., Gu, J., & Ao, P. (2014) · Interface Focus · doi:10.1098/rsfs.2013.0064 · Cited by 34
Frequent BRAF Gain in Low‐Grade Diffuse Gliomas with 1p/19q Loss
Kim, Y., Nonoguchi, N., Paulus, W., Brokinkel, B., Keyvani, K., Sure, U., Wrede, K. H., Mariani, L., Giangaspero, F., Tanaka, Y., et al. (2012) · Brain Pathology · doi:10.1111/j.1750-3639.2012.00601.x · Cited by 36
p21-Activated Kinase Inhibitors
Rudolph, J., Crawford, J. J., Hoeflich, K. P., & Chernoff, J. (2013) · The Enzymes · doi:10.1016/b978-0-12-420146-0.00007-x · Cited by 37
β 2 -receptor agonists salbutamol and terbutaline attenuated cytokine production by suppressing ERK pathway through cAMP in macrophages
Keränen, T., Hömmö, T., Moilanen, E., & Korhonen, R. (2017) · Cytokine · doi:10.1016/j.cyto.2016.07.016 · Cited by 36
OTX1 Contributes to Hepatocellular Carcinoma Progression by Regulation of ERK/MAPK Pathway
Li, H., Miao, Q., Xu, C., Huang, J.-H., Zhou, Y.-F., & Wu, M. (2016) · Journal of Korean Medical Science · doi:10.3346/jkms.2016.31.8.1215 · Cited by 34
The “SWOT” of BRAF Inhibition in Melanoma: RAF Inhibitors, MEK Inhibitors or Both?
Nissan, M. H., & Solit, D. B. (2011) · Current Oncology Reports · doi:10.1007/s11912-011-0198-4 · Cited by 33
Self-citation
A phase I study of binimetinib (MEK162) in Japanese patients with advanced solid tumors
Watanabe, K., Otsu, S., Hirashima, Y., Morinaga, R., Nishikawa, K., Hisamatsu, Y., Shimokata, T., Inada‐Inoue, M., Shibata, T., Takeuchi, H., et al. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3019-5 · Cited by 33
Strategies for Overcoming Resistance in Tumours Harboring BRAF Mutations
Obaid, N., Bedard, K., & Huang, W. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18030585 · Cited by 37
Targeting DUSP s in glioblastomas – wielding a double‐edged sword?
Prabhakar, S., Asuthkar, S., Lee, W. E., Chigurupati, S., Zakharian, E., Tsung, A. J., & Velpula, K. K. (2013) · Cell Biology International · doi:10.1002/cbin.10201 · Cited by 32
Deregulated apoptosis signaling in core-binding factor leukemia differentiates clinically relevant, molecular marker-independent subgroups
Lück, S. C., Russ, A. C., Botzenhardt, U., Paschka, P., Schlenk, R. F., Döhner, H., Fulda, S., Döhner, K., & Bullinger, L. (2011) · Leukemia · doi:10.1038/leu.2011.154 · Cited by 31
BAG3 Down-Modulation Reduces Anaplastic Thyroid Tumor Growth by Enhancing Proteasome-Mediated Degradation of BRAF Protein
Chiappetta, G., Basile, A. M., Arra, C., Califano, D., Pasquinelli, R., Barbieri, A., Simone, V. D., Rea, D., Giudice, A., Pezzullo, L., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0484 · Cited by 30
Expression of KITENIN in human colorectal cancer and its relation to tumor behavior and progression
Lee, S., Song, Y., Park, Y., Cho, S., Lee, W., Lee, J., Chung, I., Kim, K. K., Rew, J., & Joo, Y. (2011) · Pathology International · doi:10.1111/j.1440-1827.2011.02646.x · Cited by 29
Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance
Wheler, J. J., Yelensky, R., Falchook, G. S., Kim, K. B., Hwu, P., Tsimberidou, A. M., Stephens, P. J., Hong, D. S., Cronin, M. T., & Kurzrock, R. (2015) · BMC Cancer · doi:10.1186/s12885-015-1029-z · Cited by 28
New druggable targets in the Ras pathway?
Matallanas, D., & Crespo, P. (2010) · PubMed · Cited by 28
Key roles of EMT for adaptive resistance to MEK inhibitor in KRAS mutant lung cancer
Kitai, H., & Ebi, H. (2016) · Small GTPases · doi:10.1080/21541248.2016.1210369 · Cited by 28
Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers
Adachi, Y., Kimura, R., Hirade, K., & Ebi, H. (2021) · Cancers · doi:10.3390/cancers13205081 · Cited by 28
Platelet-Derived Growth Factor-BB Inhibits Intervertebral Disc Degeneration via Suppressing Pyroptosis and Activating the MAPK Signaling Pathway
Zhang, W., Gong, Y., Zheng, X., Qiu, J., Jiang, T., Chen, L., Lu, F., Wu, X., Cheng, F., & Hong, Z. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.799130 · Cited by 26
An updated literature on BRAF inhibitors (2018–2023)
Maji, L., Teli, G., Raghavendra, N. M., Sengupta, S., Pal, R., Ghara, A., & Matada, G. S. P. (2023) · Molecular Diversity · doi:10.1007/s11030-023-10699-3 · Cited by 27
Current advances and perspectives in the treatment of advanced melanoma
Livingstone, E., Zimmer, L., Vaübel, J., & Schadendorf, D. (2012) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/j.1610-0387.2012.07895.x · Cited by 26
Ell3 stimulates proliferation, drug resistance, and cancer stem cell properties of breast cancer cells via a MEK/ERK-dependent signaling pathway
Ahn, H.-J., Kim, G., & Park, K. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.06.114 · Cited by 25
First SAR Study for Overriding NRAS Mutant Driven Acute Myeloid Leukemia
Cho, H., Shin, I., Ju, E., Choi, S.-H., Hur, W., Kim, H., Hong, E., Kim, N. D., Choi, H. G., Gray, N. S., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00882 · Cited by 25
Development of ERK1/2 inhibitors as a therapeutic strategy for tumour with MAPK upstream target mutations
Miao, L., & Tian, H. (2019) · Journal of drug targeting · doi:10.1080/1061186x.2019.1648477 · Cited by 24
PLX4032: does it keep its promise for metastatic melanoma treatment?
Livingstone, E., Zimmer, L., Piel, S., & Schadendorf, D. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.527945 · Cited by 24
Case-specific potentiation of glioblastoma drugs by pterostilbene
Schmidt, L., Baskaran, S., Johansson, P., Padhan, N., Matuszewski, D. J., Green, L. C., Elfineh, L., Wee, S., Häggblad, M., Märtens, U., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12298 · Cited by 23
Profile of selumetinib and its potential in the treatment of melanoma
Patel, S. P., & Kim, D. W. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s51596 · Cited by 23
The promise of signal transduction in genetically driven sarcomas of the nerve
Kim, A., & Pratilas, C. A. (2017) · Experimental Neurology · doi:10.1016/j.expneurol.2017.08.014 · Cited by 22
Self-citation
Role of the ERK1/2 pathway in tumor chemoresistance and tumor therapy.
Liu, Q.-H., Shi, M.-L., Sun, C., Bai, J., & Zheng, J.-N. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.11.076 · Cited by 17
RON is associated with tumor progression via the inhibition of apoptosis and cell cycle arrest in human gastric cancer
Song, Y., Park, Y., Kim, K., Myung, E., Chung, C., Cho, S., Lee, W., Jung, Y., Kweon, S., & Joo, Y. (2011) · Pathology International · doi:10.1111/j.1440-1827.2011.02765.x · Cited by 21
Electrochemically Reduced Water Delays Mammary Tumors Growth in Mice and Inhibits Breast Cancer Cells Survival In Vitro
Frajese, G. V., Benvenuto, M., Mattera, R., Giampaoli, S., Ambrosin, E., Bernardini, R., Giganti, M. G., Albonici, L., Dus, I., Manzari, V., et al. (2018) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2018/4753507 · Cited by 21
Phosphoprotein pathway profiling of ovarian carcinoma for the identification of potential new targets for therapy
Faratian, D., Um, I., Wilson, D. S., Mullen, P., Langdon, S. P., & Harrison, D. J. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.01.014 · Cited by 19
Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS- or BRAF-mutated melanoma
van Herpen, C. V., Agarwala, S., Hauschild, A., Berking, C., Beck, J. T., Schadendorf, D., Jansen, R., Queirolo, P., Ascierto, P., Blank, C. U., et al. (2019) · OncoTarget · doi:10.18632/oncotarget.26753 · Cited by 17
Computational Analyses of Synergism in Small Molecular Network Motifs
Zhang, Y., Smolen, P. D., Baxter, D. A., & Byrne, J. H. (2014) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003524 · Cited by 20
Cancer Cells‘ Epigenetic Composition And Predisposition to Histone Deacetylase Inhibitor Sensitization
Nalabothula, N., & Carrier, F. (2011) · Epigenomics · doi:10.2217/epi.11.12 · Cited by 21
Sarsaparilla ( Smilax Glabra Rhizome) Extract Inhibits Cancer Cell Growth by S Phase Arrest, Apoptosis, and Autophagy via Redox-Dependent ERK1/2 Pathway
She, T., Qu, L., Wang, L., Yang, X., Xu, S., Feng, J., Gao, Y., Zhao, C., Han, Y. K., Cai, S., et al. (2015) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-14-0372 · Cited by 20
Therapeutic Inhibitors against Mutated BRAF and MEK for the Treatment of Metastatic Melanoma
Ryu, S., Youn, C.-K., Moon, A. R., Howland, A., Armstrong, C. A., & Song, P. I. (2017) · Chonnam Medical Journal · doi:10.4068/cmj.2017.53.3.173 · Cited by 20

Authors: Pratilas, C. A., & Solit, D. B.
Affiliations: Memorial Sloan Kettering Cancer Center (US)
Corresponding author: Solit, David B.
ORCID: Pratilas, Christine A.
Solit, David B.
Venue: Clinical Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2010-06-30
Volume: 16
Issue: 13
Pages: 3329-3334
ISSN: 1078-0432 (ISSN-L)
1557-3265
DOI: 10.1158/1078-0432.ccr-09-3064
PMC: PMC2912210
OpenAlex: W2079576402
Cited by: 183
References: 74
Citations by year: 2026: 5 · 2025: 7 · 2024: 2 · 2023: 7 · 2022: 7 · 2021: 6 · 2020: 5 · 2019: 9 · 2018: 9 · 2017: 9 · 2016: 14 · 2015: 9 · 2014: 17 · 2013: 21 · 2012: 20
FWCI: 2.13
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Clinical Cancer Research (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (R01CA127240, K08CA127350, P30CA008748, P50CA092629)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
Keywords: MAPK signaling, BRAF V600E mutation, RAS mutations, BRAF inhibitors, vemurafenib, physiological feedback, acquired drug resistance, targeted therapy, combination therapy, predictive biomarkers
MeSH terms: Antineoplastic Agents, Humans, Neoplasms, Genes, ras, Signal Transduction, Drug Delivery Systems, Mitogen-Activated Protein Kinases, Feedback, Physiological, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Targeting the Mitogen-Activated Protein Kinase Pathway: Physiological Feedback and Drug Response

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks